for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Avita Therapeutics Inc

AVH.AX

Latest Trade

7.18AUD

Change

0.02(+0.28%)

Volume

160,340

Today's Range

7.10

 - 

7.33

52 Week Range

0.32

 - 

9.58

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
7.16
Open
7.21
Volume
160,340
3M AVG Volume
13.96
Today's High
7.33
Today's Low
7.10
52 Week High
9.58
52 Week Low
0.32
Shares Out (MIL)
1,871.30
Market Cap (MIL)
732.89
Forward P/E
-61.15
Dividend (Yield %)
--

Latest Developments

更多

Avita Therapeutics FY Sales 14.32 Million USD

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Avita Therapeutics Inc

AVITA Therapeutics, Inc., formerly Avita Medical Limited, is a regenerative medicine company with a technology platform to address medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. Its technology provides treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. Its product, the RECELL System for the treatment of acute thermal burn injuries in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patient’s own skin, providing a way to treat severe burns that significantly reduces the amount of donor skin required. It is designed to be used at the point of care alone or in combination with split-thickness skin autografts depending on the depth of the burn injury.

Industry

Biotechnology & Drugs

Contact Info

28159 Avenue Stanford, Suite 220

VALENCIA, CA

91355

United States

+1.661.3679170

https://www.avitamedical.com/

Executive Leadership

Lou Panaccio

Independent Non-Executive Chairman of the board

Michael S. Perry

Chief Executive Officer, Executive Director

David John McIntyre

Chief Financial Officer

Andrew Quick

Chief Technology Officer

Donna Shiroma

General Counsel

Key Stats

1.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, AUD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (AUD)

2018

-0.360

2019

-0.540

2020

-0.618

2021(E)

-0.687
Price To Earnings (TTM)
--
Price To Sales (TTM)
45.17
Price To Book (MRQ)
593.17
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
3.10
LT Debt To Equity (MRQ)
2.52
Return on Investment (TTM)
-51.04
Return on Equity (TTM)
-47.05

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up